Greenwich Weighted Average Shares Diluted Trend from 2010 to 2022

GLSI
 Stock
  

USD 8.76  0.20  2.23%   

Greenwich Lifesciences Weighted Average Shares Diluted is increasing over the last several years with slightly volatile swings. Weighted Average Shares Diluted is predicted to flatten to about 10.4 M. During the period from 2010 to 2022 Greenwich Lifesciences Weighted Average Shares Diluted regressed destribution of quarterly values had coefficient of variationof 165.91 and r-squared of  0.58. The current Consolidated Income is estimated to decrease to about (4.9 M). The current Earning Before Interest and Taxes EBIT is estimated to decrease to about (4.9 M).
  
Refresh
Check Greenwich Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Greenwich main balance sheet or income statement drivers, such as Operating Expenses of 4.1 M, Research and Development Expense of 3.1 M or Selling General and Administrative Expense of 992.8 K, as well as many exotic indicators such as Book Value per Share of 2.24, Current Ratio of 76.24 or Debt to Equity Ratio of 0.0151. Greenwich financial statements analysis is a perfect complement when working with Greenwich Lifesciences Valuation or Volatility modules. It can also supplement various Greenwich Lifesciences Technical models. Please check the analysis of Greenwich Lifesciences Correlation against competitors.

Greenwich Lifesciences Quarterly Weighted Average Shares Diluted

13.06 Million

Share

Greenwich Weighted Average Shares Diluted Breakdown

Showing smoothed Weighted Average Shares Diluted of Greenwich Lifesciences with missing and latest data points interpolated. The weighted average number of shares or units issued and outstanding that are used by the company to calculate [EPSDil]; determined based on the timing of issuance of shares or units in the period.Greenwich Lifesciences' Weighted Average Shares Diluted historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Greenwich Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Weighted Average Shares Diluted10 Years Trend
Increasing
Slightly volatile
 Weighted Average Shares Diluted 
Share
      Timeline 

Greenwich Weighted Average Shares Diluted Regression Statistics

Arithmetic Mean 2,841,961
Geometric Mean 612,092
Coefficient Of Variation 165.91
Mean Deviation 3,743,796
Median 202,996
Standard Deviation 4,715,008
Range 12,741,138
R-Value 0.76
R-Squared 0.58
Significance 0.002364
Slope 924,950

Greenwich Weighted Average Shares Diluted History

20192.3 M
20209.5 M
202112.9 M
202210.4 M

About Greenwich Lifesciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Greenwich Lifesciences income statement, its balance sheet, and the statement of cash flows. Greenwich Lifesciences investors use historical funamental indicators, such as Greenwich Lifesciences's Weighted Average Shares Diluted, to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences investors may use each financial statement separately, they are all related. The changes in Greenwich Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Greenwich Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Greenwich Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Greenwich Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Weighted Average Shares Diluted12.9 M10.4 M
Average Assets29.1 M23.7 M
Average Equity28.6 M30.8 M
Invested Capital Average-541.5 K-584.3 K
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Greenwich Lifesciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Greenwich Lifesciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of Greenwich Lifesciences Correlation against competitors. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
116.5 M
Return On Assets
-0.15
Return On Equity
-0.24
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.